ResApp Health Limited and Coviu have entered into a non-binding memorandum of understanding (MOU) to integrate ResApp's acute respiratory diagnostic test, ResAppDx-EU into Coviu's browser-based telehealth platform. The integration will see ResAppDx-EU become available to the 5,500+ clinicians who currently use the Coviu platform. Clinicians will then have the ability to accurately diagnose respiratory disease in a telehealth setting. Most people will develop an acute respiratory tract infection every year, and up to a half of all telehealth consultations are respiratory-related. Standard diagnostic aids such as stethoscopes are unavailable during a video-based telehealth consultation. A spinout from CSIRO's Data61, Coviu's telehealth platform makes it easy for healthcare providers to offer their services directly to patients via video consultation and powers the Australian government-funded healthdirect Video Call. Coviu hosts video consultations for over 5,500 clinicians and over 1,000 individual clinics, offering the potential to reach millions of Australians. ResAppDx-EU is a software application used by clinicians to diagnose the most common respiratory diseases. The software uses machine learning algorithms that analyse a patient's cough sounds to diagnose disease. ResAppDx-EU is CE Marked in the European Union and Therapeutics Good Administration (TGA) approved in Australia.